

Session 9.2

Data Integration Platform – Implementation & Validation Challenges

Grzegorz Janczewski | Rezon Bio



Data Integration Platform

➤ Implementation and validation challenges



Table of contents

01 Rezon Bio Overview

02 Data-driven organization

03 Challenges vs Reality

04 Good practices & Solution

05 Kneat Gx user experience



➤ End-to-End CDMO solutions for scalability, speed & quality

Cell line development



High-yield mammalian cell lines tailored for fast timelines & manufacturability*

Clinical & commercial drug substance GMP manufacturing



Flexible capacity, inspection-ready operations, highly competitive pricing

Drug product development



Expertise aligning formulation, device, and packaging strategies with clinical needs

Drug substance process development



Scalable upstream and downstream processes built for robustness

Analytical capabilities



Development and Quality Control: Phase-appropriate method development, CQA-driven assay strategies, qualified release testing.

Drug product GMP manufacturing



Ready-to-fill formulations, supply of vials or assembly of drug devices*

Supporting Services

- ✓ Device development
- ✓ Tech transfers (analytical/process)
- ✓ PAI support
- ✓ Regulatory support
- ✓ Process characterization
- ✓ PPQ

* Delivered by trusted and qualified external partners

➤ Integrated state-of-the-art facilities & services



Phase-appropriate services, spanning from cell line development to commercial supply. Mirrored equipment, processes, and analytical approaches enable seamless scale-up to serve clients worldwide.

Clinical development & manufacturing

➤ Gdańsk, Poland

- ✓ AI-supported manufacturing lines
- ✓ Fast, first-in-human batches
- ✓ Analytical & process development for quality, robustness & scalability
- ✓ FDA, EMA, ANVISA, MHRA approved
- ✓ Up to 2×1,000L SU scale



Commercial scale GMP manufacturing

➤ Warsaw-Duchnice, Poland

- ✓ Extensive capacity supports increasing scale
- ✓ Fast & flexible scheduling
- ✓ Cost-efficient
- ✓ Quick multi-product turnover
- ✓ FDA, EMA approved
- ✓ Up to 2×2,000L SU scale



Disclaimer

This presentation is intended solely for informational and training purposes. All content in this presentation is protected by copyright and remains the exclusive property of Polpharma Biologics S.A. acting under Rezon Bio brand. No part of this presentation may be copied, reproduced, distributed, published, or disclosed to any third party without the prior consent of Polpharma Biologics S.A. acting under Rezon Bio brand. The content of this presentation is not intended to constitute legal or professional advice and should not be relied upon as such.





Table of contents

01 Rezon Bio Overview

02 Data-driven organization

03 Challenges vs Reality

04 Good practices & Solution

05 Kneat Gx user experience



Why data-driven?

Market saturation

CDMO market is growing

... so as the number of competitors

Growing expectations

Clients expect more

... and faster

Cost pressure

Budgets are smaller

... but the workload is growing

Staying competitive requires data-driven organization



Removing data access barriers



Increasing cross org data visibility




Preparing for the era of Artificial Intelligence






From idea to operational reality



Business purpose and intended use



Digital Maturity Growth



System architecture






Table of contents

01 Rezon Bio Overview

02 Data-driven organization

03 Challenges vs Reality

04 Good practices & Solution

05 Kneat Gx user experience



Challenges






Table of contents

01 Rezon Bio Overview

02 Data-driven organization

03 Challenges vs Reality

04 Good practices & Solution

05 Kneat Gx user experience



#1 Virtual infrastructure



ISPE GAMP Good Practice Guide: IT Infrastructure Control and Compliance, Second Edition
Appendix 12 – Virtualization: Compliance and Control

- "... infrastructure platforms and components may be qualified independently of the validation of the dependent systems, as long as the infrastructure is properly specified, verified, controlled, and maintained"
- „ ... risks are unique to the virtualized environment and will require specific risk assessments to be conducted ..."
- "... procedures should be specific to the virtualized environment"





#1 Virtual infrastructure

Initial risk assessment
–
complexity and GxP
impact.

Information security
risk analysis
–
potential vulnerabilities.

User requirements
–
20 requirements for
network and
infrastructure.

Specifications

- Data Platform Infrastructure specification
- Data Platform Infrastructure deployment specification

Maintenance processes

restore and disaster recovery,
change and patch
management,
access management

#2 Open-source software



ISPE GAMP 5 Guide: A-Risk-Based approach to Compliant GxP Computerized Systems, Second Edition
Appendix D4, Section 24.3.3. Third-Party Software

- "Note that commercial software may contain open-source components ..."
- "Evaluation of software control for OSS is similar in scope and approach to that of purchased software"
- "...a risk assessment should be performed to determine the business and GxP risk..."
- "Such software should be implemented in accordance with the appropriate life cycle activities as for commercial software ..."



#2 Open-source software



Functional Risk Assessment

- Risk assessment for every OSS

Specification

- each OSS is specified and configured

Version control

- installed On Prem,
- patches are fully under control

Vulnerability

- OSS not exposed to the internet,
- each OSS was assessed by Information Security team

Testing

- limited to the intended use
- appropriate to the results of functional risk assessment

#3 Custom software




ISPE GAMP 5 Guide: A-Risk-Based approach to Compliant GxP Computerized Systems, Second Edition
Appendix D8 Agile Software Development

- "Agile is not a reason to accept the lower level of quality or GxP compliance."
- "For agile, testing is always performed (...) an untested product is not shippable."
- "The regulated user must ensure the computerized system is fit for intended use."
- "Evidence of this may be generated and maintained in tools and supporting systems"



Solution

#3 Custom software



#4 Software development & validation



Eudralex Volume 4 Annex 11


- 4.6 "For the validation of bespoke or customised computerised systems there should be a process in place that ensures the formal assessment ...".

Eudralex Volume 4 Annex 15

- 1.2 "Qualification and validation activities should only be performed by suitably trained personnel who follow approved procedures."
- "Verification of the correct installation [IQ] against pre-defined criteria"



#4 Software development & validation



#5 Risk assessment & risk management

ISPE GAMP 5 Guide: A-Risk-Based approach to Compliant GxP Computerized Systems, Second Edition
Appendix M4 Categories of Software and Hardware

- There are two main ways to use the categories:
 - Whole-system assessment
 - Functional risk assessment
- Functional risk assessment
 - Increasing risk of failure occurrence from standard to custom software
 - Increasing risk of failure detection from standard to custom software



#5 Risk assessment & risk management

Occurrence and detectability depends on function implementation types:

Category 3

- Standard function
 - the risk should not be high

Category 4

- Configurable function
 - the risk might be medium

Category 5

- Custom-made function
 - the risk should not be low

#6 Source code



ISPE GAMP 5 Guide: A-Risk-Based approach to Compliant GxP Computerized Systems, Second Edition

- Appendix D4: Management, development, and review of software
 - "The [source code] review should be performed by at least one independent person with sufficient knowledge"
- Appendix M12: Critical thinking
 - "Information and test evidence in the form of artifacts within (...) automated test tools have the same status as formal documentation,"
- Appendix D9: Software tools
 - "Tools, like system supporting IT processes, are all GAMP category 1"
 - "Such tools and systems supporting system life cycle, IT processes and infrastructure should not be subject to specific validation"
 - "GAMP and FDA Case for Quality program strongly encourage the use of software lifecycle management tools"
 - "Tools should have sufficient controls to preserve the data/records"



#6 Source code



Microsoft Azure DevOps

Code
Management

Code
Review

Code
Approval

Code
Review
Good
Practices
document

#7 Testing




ISPE GAMP 5 Guide: A-Risk-Based approach to Compliant GxP Computerized Systems, Second Edition
Appendix D5: Testing of computerized systems

- "Testing may take place in different environments during a project: development, formal testing, operational.
- "The test environments (...) need to be functionally equivalent for the testing to be representative..."
- "...there is no benefit to repeating testing already performed in another, but still adequately controlled environment just because it was not the formal test environment,"



Solution

#7 Testing



#8 Data integrity




Eudralex Volume 4, Annex 11

- 4.8 If data are transferred to another data format or system, validation should include checks that data are not altered in value and/or meaning during this migration process.



#8 Data integrity & data management




#8 Data integrity & data management



- MHRA (UK) GMP Data Integrity Initiatives
- WHO Guidance on Good Data and Records Management Practices
- PIC/S PI-041 Data Integrity Guidance
- FDA Guidance on Data Integrity and Compliance with CGMP
- EMA Guideline on computerised systems and electronic data in clinical trials
- ISPE Records and Data Integrity Guides
- DAMA Data Management Body of Knowledge



#8 Data integrity & data management



Company

- New unit within IT department
"Data Intelligence & Data Platforms"


Process

- Data policy and procedures update


System

- Data integrity control points and mapping

#9 Supplier involvement



#9 Supplier involvement





Takeaways

1. Regulations do not limit your validation process – your procedures do.
2. A risk-based validation approach is crucial for custom software.
3. You are not alone; your supplier can provide significant support.
4. Data integrity and data management must be ensured at



Table of contents

01 Rezon Bio Overview

02 Data-driven organization

03 Challenges vs Reality

04 Good practices & Solution

05 Kneat Gx user experience



Kneat Gx experience

- SPECs – we have started in SharePoint and documents were moved to Kneat Gx (import from Word) for review, corrections, and approval.
- FRA – created in Excel and attached to Kneat Gx. I regret not using Risk Entities.
- Traceability – Kneat Gx is a useful tool to create the requirements traceability (but we made a mistake)
- RTM – fully generated by Kneat Gx, over 1200 rows
- Test cases – created in SharePoint and moved to Kneat Gx test protocols
- Review & approval process – very efficient, users were satisfied
- User license consumption – improved due to active / inactive switch
- User experience – positive for both Standard Users and Review & Approval User

Thank you! Questions?



Where dedication delivers
program success

Grzegorz Janczewski

CSV Manager, IT Department



grzegorz.janczewski@rezonbio.com

Development & Production Center
in Gdańsk

ul. Trzy Lipy 3
80-172 Gdańsk, Poland

Development & Production Center
in Warsaw – Duchnice

ul. Spółdzielcza 4
05-850 Duchnice, Poland



Learn
more at
www.rezonbio.com